2 ASX shares experts think will smash the market in 2026!

If you are looking for big returns in 2026, then read on!

That’s because experts believe that the ASX shares in this article have the potential to smash the market next year.

Here’s what they are recommending to clients for the year ahead:

Catapult Sports Ltd (ASX: CAT)

The team at Morgans thinks that this sports technology company’s shares could be strong performers in 2026.

Its analysts have put a buy rating and $6.25 price target on the ASX share. Based on its current share price of $4.14, this implies potential upside of 50% for investors over the next 12 months.

Morgans thinks that Catapult is well-placed to deliver strong top line growth through to at least 2028. It said:

Catapult Sports Ltd (CAT) is a global leader in sports performance technology that provides a comprehensive all-in-one platform for elite professional and collegiate sports. This encompasses coaching, scouting, analytics and athlete management. Initially landing with its core wearables technology, CAT has since expanded its service offering and opened up new key verticals assisting its penetration into a large addressable market of ~20k teams globally. We forecast strong topline growth for CAT, estimating a ~20% ACV 3-year CAGR, reaching ~US$180m by FY28. A scalable platform and strong SaaS metrics should see CAT join the ‘Rule of 40’ club by FY27. We initiate coverage on Catapult Sports (CAT) with a Buy recommendation and a A$6.25 per share price target.

Telix Pharmaceuticals Ltd (ASX: TLX)

Another ASX share with the potential to deliver big returns next year according to experts is radiopharmaceuticals company Telix.

Bell Potter has a buy rating and $23.00 price target on its shares. This is almost double its current share price.

The broker is expecting a better year for Telix, supported by the potential approval of its Zircaix product. It explains:

We are confident regarding the approval in CY 2026 of Zircaix following resubmission of the Biological License Application (BLA). The FDA rejected the original BLA due to CMC (chemistry manufacturing & control) matters at Telix’s manufacturing partner. There were no matters related to safety or efficacy. We expect the market for Zircaix once approved will be in excess of US$500m. The product has been included in guidelines for disease management in the US and Europe and continues to be available in the US under the expanded access program. Elsewhere, sales of Iluuccix/ Gozellix in the PSMA franchise continue to grow and were recently boosted by the refresh on the pass through pricing.

The post 2 ASX shares experts think will smash the market in 2026! appeared first on The Motley Fool Australia.

More reading

• 10 ASX shares I would buy in 2026
• In 2036, you will be glad you bought these ASX shares today
• 5 ASX tech shares to buy and hold until 2035
• These are the 10 most shorted ASX shares
• 2 ASX 200 shares down 30% or more that could be a new years buy

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended Catapult Sports. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.